Ut enim ad minim veniam, quis nostrud 

Lynx Biosciences, Inc. (LynxBio®) is a clinical-stage biotechnology company combining physiologically relevant suspension cell co-culture assays, automated microfluidics, and deep learning analytics with the goal of rapidly advancing drug candidates in oncology and bringing personalized cancer treatments to patients.

​

As a (re)mission-driven company, we leverage this clinically-proven platform to address unmet medical needs in oncology, with an initial focus on hematological malignancies. To date, we have entered into collaborations with 10+ NCI-designated cancer centers as well as Top 20 pharmaceutical companies to advance promising drug candidates and identify predictive biomarkers in clinical studies.

Board of Directors

Board of Advisors

Clinical partners